Ignite Proteomics公布了一项前瞻性肿瘤登记研究计划，拟纳入10,000名患者，旨在评估功能性蛋白质组学在癌症治疗方案选择中的实际应用价值。该大规模注册研究将系统性地收集真实世界数据，以深入分析基于蛋白质功能特征的检测方法如何优化临床治疗决策，并探索其在提升患者疗效与生存结局方面的潜力。
Ignite Proteomics公布了一项前瞻性肿瘤登记研究计划，拟纳入10,000名患者，旨在评估功能性蛋白质组学在癌症治疗方案选择中的实际应用价值。该大规模注册研究将系统性地收集真实世界数据，以深入分析基于蛋白质功能特征的检测方法如何优化临床治疗决策，并探索其在提升患者疗效与生存结局方面的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.